de Maat MPM - Search Results

1

Rosuvastatin use increases plasma fibrinolytic potential: a randomised clinical trial.

Schol-Gelok S, de Maat MPM, Biedermann JS, van Gelder T, Leebeek FWG, Lijfering WM, van der Meer FJM, Rijken DC, Versmissen J, Kruip MJHA. Schol-Gelok S, et al. Among authors: de maat mpm. Br J Haematol. 2020 Sep;190(6):916-922. doi: 10.1111/bjh.16648. Epub 2020 Apr 16. Br J Haematol. 2020. PMID: 32301122 Free PMC article. Clinical Trial.

2

A shift in balance between profibrinolytic and antifibrinolytic factors causes enhanced fibrinolysis in cirrhosis.

Leebeek FW, Kluft C, Knot EA, de Maat MP, Wilson JH. Leebeek FW, et al. Gastroenterology. 1991 Nov;101(5):1382-90. doi: 10.1016/0016-5085(91)90092-y. Gastroenterology. 1991. PMID: 1718809

3

Histidine-rich glycoprotein is elevated in mild liver cirrhosis and decreased in moderate and severe liver cirrhosis.

Leebeek FW, Kluft C, Knot EA, De Maat MP. Leebeek FW, et al. J Lab Clin Med. 1989 Apr;113(4):493-7. J Lab Clin Med. 1989. PMID: 2703760

4

Inactivation of single-chain urokinase-type plasminogen activator by thrombin in human subjects.

Braat EA, Levi M, Bos R, Haverkate F, Lassen MR, de Maat MP, Rijken DC. Braat EA, et al. J Lab Clin Med. 1999 Aug;134(2):161-7. doi: 10.1016/s0022-2143(99)90121-x. J Lab Clin Med. 1999. PMID: 10444030 Clinical Trial.

5

Association between thrombin-activatable fibrinolysis inhibitor (TAFI) and clinical outcome in patients with unstable angina pectoris.

Brouwers GJ, Leebeek FW, Tanck MW, Wouter Jukema J, Kluft C, de Maat MP. Brouwers GJ, et al. Thromb Haemost. 2003 Jul;90(1):92-100. Thromb Haemost. 2003. PMID: 12876631

6

Elevated levels of von Willebrand Factor in cirrhosis support platelet adhesion despite reduced functional capacity.

Lisman T, Bongers TN, Adelmeijer J, Janssen HL, de Maat MP, de Groot PG, Leebeek FW. Lisman T, et al. Hepatology. 2006 Jul;44(1):53-61. doi: 10.1002/hep.21231. Hepatology. 2006. PMID: 16799972

7

High von Willebrand factor levels increase the risk of first ischemic stroke: influence of ADAMTS13, inflammation, and genetic variability.

Bongers TN, de Maat MP, van Goor ML, Bhagwanbali V, van Vliet HH, Gómez García EB, Dippel DW, Leebeek FW. Bongers TN, et al. Stroke. 2006 Nov;37(11):2672-7. doi: 10.1161/01.STR.0000244767.39962.f7. Epub 2006 Sep 21. Stroke. 2006. PMID: 16990571

8

Genetic variation in thrombin-activatable fibrinolysis inhibitor (TAFI) is associated with the risk of splanchnic vein thrombosis.

de Bruijne EL, Darwish Murad S, de Maat MP, Tanck MW, Haagsma EB, van Hoek B, Rosendaal FR, Janssen HL, Leebeek FW; Liver and Thrombosis Study Group. de Bruijne EL, et al. Thromb Haemost. 2007 Feb;97(2):181-5. Thromb Haemost. 2007. PMID: 17264944

9

Prothrombotic coagulation abnormalities in patients with paraprotein-producing B-cell disorders.

Auwerda JJ, Sonneveld P, de Maat MP, Leebeek FW. Auwerda JJ, et al. Clin Lymphoma Myeloma. 2007 Jul;7(7):462-6. doi: 10.3816/clm.2007.n.027. Clin Lymphoma Myeloma. 2007. PMID: 17875234

10

Variation in fibrinogen FGG and FGA genes and risk of stroke: the Rotterdam Study.

Cheung EY, Bos MJ, Leebeek FW, Koudstaal PJ, Hofman A, de Maat MP, Breteler MM. Cheung EY, et al. Thromb Haemost. 2008 Aug;100(2):308-13. Thromb Haemost. 2008. PMID: 18690352

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

329 results

Search Page

Filters